Insulin Resistance News and Research

RSS

Insulin Resistance is a condition in which the body does not respond to insulin properly. This is most common in Type II diabetes or associated with obesity, ketoacidosis, infection, and certain rare conditions. Diminished effectiveness of insulin in lowering blood glucose levels requiring 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

Discovery of omega-3 fatty acid molecular mechanism paves way for development of dietary remedy for diabetes

Researchers at the University of California, San Diego School of Medicine have identified the molecular mechanism that makes omega-3 fatty acids so effective in reducing chronic inflammation and insulin resistance.

3 Sep 2010

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer's disease, according to new research published in the August 25, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2010

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Skeletal muscles combust both lipids and carbohydrates during exercise. The carbohydrates consist of both glycogen stored in the muscles as well as glucose extracted from the blood. Being a major sink for glucose disposal, skeletal muscle represents an important model tissue for studying the intracellular signaling pathways leading to increased glucose transport.

21 Aug 2010

Scientist suggests emodin can reduce impact of type 2 diabetes

Emodin, a natural product that can be extracted from various Chinese herbs including Rheum palmatum and Polygonum cuspidatum, shows promise as an agent that could reduce the impact of type 2 diabetes. Findings published in this month's edition of the British Journal of Pharmacology show that giving emodin to mice with diet-induced obesity lowered blood glucose and serum insulin, improved insulin resistance and lead to more healthy levels of lipid in the blood. It also decreased body weight and reduced central fat mass.

18 Aug 2010

Scientists experiment with three proteins that impact preadipocytes contribute to fat cell determination

Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.

17 Aug 2010

Obesity diabetes link found

Melbourne researchers from the Walter and Eliza Hall Institute have found that inflammatory cells in fat tissue cause the body to become resistant to the effects of insulin – a common precursor to type II diabetes.

16 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Eliminating depression, diabetes can reduce levels of dementia: Study

Eliminating diabetes and depression, as well as increasing education and fruit and vegetable consumption, are likely to have the biggest impact on reducing levels of dementia in the coming years, should no effective treatment be found, concludes a study published on bmj.com today.These findings suggest priorities for future public health interventions.While the exact cause of dementia is still unknown, several modifiable risk factors have already been identified. These include vascular risk factors (heart disease, stroke, high blood pressure, obesity, diabetes, and high cholesterol), a history of depression, diet, alcohol consumption, and education level.

6 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

Resveratrol suppresses inflammation in humans: Research

Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based on results from the first prospective human trial of the extract conducted by University at Buffalo endocrinologists.

31 Jul 2010

Resveratrol suppresses inflammation and free radicals: Study

30 Jul 2010

Orexigen's Contrave COR-I trial results published online in journal Lancet

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

30 Jul 2010

Researchers examine why some obese people become diabetic while others do not

Why some obese people go on to become diabetic while others do not. It is common to find obese people - even morbidly obese people - who are healthier than their condition would normally allow.

29 Jul 2010

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

29 Jul 2010

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump out unwanted or toxic substances, will announce new results from human trials of its lead compound, LIM-0705, at the 23rd International Congress of the Transplantation Society in Vancouver, Canada, in an oral presentation on August 19, 2010.

29 Jul 2010

HIV drug can raise the risk of heart disease: Study

There are a handful of drugs effective in treating HIV/AIDS. However new research shows that some of these drugs can increase the risk of heart attacks. The results come from a Garvan Institute of Medical Research study involving 20 people, 10 taking the drug Ritonavir and 10 others the drug Raltegravir for one month.

28 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

Insulin action may provide link between bone health, metabolic disease: Study

A new study by Johns Hopkins researchers has found that insulin, the sugar-regulating hormone, is required for normal bone development and that it may provide a link between bone health and metabolic disease, such as diabetes.

23 Jul 2010

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

A new understanding of insulin resistance and the action of diabetes drugs such as Avandia and Actos could pave the way for improved medications that are more selective and safer, say scientists from Dana-Farber Cancer Institute and The Scripps Research Institute.Our findings strongly suggest that good and bad effects of these drugs can be separated by designing second-generation drugs that focus on the newly uncovered mechanism, said Bruce Spiegelman, PhD, of Dana-Farber, senior author on a report appearing in the July 22 issue of Nature.

22 Jul 2010

Insulin Resistance News and Research

Further Reading

Discovery of omega-3 fatty acid molecular mechanism paves way for development of dietary remedy for diabetes

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Scientist suggests emodin can reduce impact of type 2 diabetes

Scientists experiment with three proteins that impact preadipocytes contribute to fat cell determination

Obesity diabetes link found

Study examines impact of microvascular decompression surgery for type 2 diabetes

Eliminating depression, diabetes can reduce levels of dementia: Study

Arena reports lower net loss of $28.80M for second-quarter 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

Resveratrol suppresses inflammation in humans: Research

Resveratrol suppresses inflammation and free radicals: Study

Orexigen's Contrave COR-I trial results published online in journal Lancet

Researchers examine why some obese people become diabetic while others do not

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

Limerick to announce new results from LIM-0705 human trials at 23rd Transplantation Society congress

HIV drug can raise the risk of heart disease: Study

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Insulin action may provide link between bone health, metabolic disease: Study

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News